Julia Sommer joined the Simons Foundation in 2011 to become a member of the team of scientists that manage SFARI’s grant portfolio and targeted projects. She mainly focuses on grants of cellular and molecular studies in autism, including many projects that make use of induced pluripotent stem cells (iPSCs). She also manages SFARI iPSC resources and, together with Brigitta Gundersen, oversees administration of SFARI annual request for Pilot and Research Award applications.
Julia Dallman is an associate professor in the Department of Biology at the University of Miami. She also directs the University of Miami Zebrafish Facility.
On 2 September, we plan to announce a new request for applications. Letters of intent, the short statements that precede full applications, are due no later than 10 October. It seems timely, therefore, to describe how we make decisions on research proposals.
This blog post accompanies the “SFARI’s 2017 funding priorities” post. In it, the SFARI science team discusses the application and review process for Pilot and Research Awards.
Today, we’re announcing our annual request for applications (RFA) for SFARI Pilot and Research Awards. Letters of intent (LOIs), the short statements that precede full applications, are due no later than 9 October, 2015. As we do every year, we’ve updated this column to provide a better picture of how the SFARI science team makes decisions on research proposals.
Today, we’re announcing a new request for applications. Letters of intent, the short statements that precede full applications, are due no later than 11 October. It seems timely, therefore, to describe how we make decisions on research proposals.
Which grant applications should SFARI choose to fund each year? The principles that guide that decision are nuanced and evolve as new results emerge. But there are some clear general guidelines in place, says John Spiro, SFARI’s deputy scientific director.
Gastrointestinal (GI) distress commonly accompanies autism spectrum disorders (ASDs), significantly impacting the quality of life of those affected and their families. Julia Dallman, in collaboration with John Rawls, plans to use zebrafish as an experimental system, since it allows for the GI tract to be imaged and manipulated in live animals. They aim to determine if GI phenotypes in multiple genetic forms of ASD are caused by convergent gut-intrinsic mechanisms. The expected outcomes would open a new field of GI research for ASD that could suggest treatment strategies for managing GI distress in humans.
On July 5, 2022, SFARI hosted an informational session on the 2022 Genomics of ASD: Pathways to Biological Convergence and Genetic Therapies request for applications (RFA). The session featured a discussion of the RFA’s objectives and priorities and an opportunity to ask questions with SFARI senior scientists Pamela Feliciano, Alan Packer, and Julia Sommer.
- Previous Page
- Viewing
- Next Page